Article
Genetic and Non-genetic Correlates of Imatinib Pharmacokinetics and Side Effects of Imatinib in Palestinian Patients with Chronic Myeloid Leukemia.
Biochemical genetics - 1 Apr 2026
Adawi Deema Hilmi, Al-Barghouthi Ahmad, Fredj Nadia Ben, Lubada Mustafa, Njjar Dania Osama, Ruzaygat Mahmoud, Hallak Hussein, Aouam Karim
Abstract excerpt
Chronic myeloid leukemia (CML) treatment with imatinib mesylate often faces challenges due to inter-patient variability in drug response and adverse effects. Genetic polymorphisms in enzymes involved in imatinib metabolism, such as CYP2C8 and CYP3A4, may contribute to this variability. This study aimed to investigate the distribution of CYP2C8*3, CYP2C8*4, and CYP3A4*22 among CML patients and evaluate their...
Topics
Join the communities discussing this publication.
